<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TNFRSF21 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TNFRSF21</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>TNF Receptor Superfamily Member 21</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>27240</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y622</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>DR6, Death Receptor 6, TR13</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6p12.1</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>426 amino acids</td>
</tr>
<tr>
<td class="label">Protein Mass</td>
<td>~48 kDa</td>
</tr>
<tr>
<td class="label">Interacting Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">APP</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">FADD</td>
<td>Death domain</td>
</tr>
<tr>
<td class="label">Caspase-6</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">Caspase-8</td>
<td>Activator</td>
</tr>
<tr>
<td class="label">TRAF2</td>
<td>Adaptor</td>
</tr>
<tr>
<td class="label">TDP-43</td>
<td>Association</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Con
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TNFRSF21 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TNFRSF21</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>TNF Receptor Superfamily Member 21</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>27240</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y622</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>DR6, Death Receptor 6, TR13</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6p12.1</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>426 amino acids</td>
</tr>
<tr>
<td class="label">Protein Mass</td>
<td>~48 kDa</td>
</tr>
<tr>
<td class="label">Interacting Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">APP</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">FADD</td>
<td>Death domain</td>
</tr>
<tr>
<td class="label">Caspase-6</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">Caspase-8</td>
<td>Activator</td>
</tr>
<tr>
<td class="label">TRAF2</td>
<td>Adaptor</td>
</tr>
<tr>
<td class="label">TDP-43</td>
<td>Association</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">22 edges</a></td>
</tr>
</table>
TNFRSF21 (Tumor Necrosis Factor Receptor Superfamily Member 21), also known as Death Receptor 6 (DR6), is a member of the tumor necrosis factor receptor superfamily. It functions as a cell surface receptor that transduces apoptotic signals and plays critical roles in both normal development and disease processes. DR6 is widely expressed in the brain and immune system, with high expression in regions affected by neurodegenerative processes including the hippocampus, cortex, and basal ganglia. This page covers the gene's molecular characteristics, normal physiological functions, disease associations, and therapeutic implications for neurodegenerative disorders.
The TNFRSF21 gene spans approximately 20 kb and contains 9 exons. It encodes a type I transmembrane protein with an extracellular domain containing four cysteine-rich repeat (CRD) motifs characteristic of the TNF receptor superfamily, a single transmembrane domain, and an intracellular death domain. The death domain enables DR6 to recruit adaptor proteins and activate caspase-dependent apoptotic signaling pathways.
DR6 contains a functional death domain that can initiate programmed cell death through both extrinsic and intrinsic pathways. Upon ligand binding or activation, DR6 recruits adaptor proteins including FADD (Fas-Associated via Death Domain) and activates downstream caspases, particularly caspase-6 and caspase-8. The receptor can also initiate apoptosis independently of ligand binding through a conformational change induced by cellular stress or protein misfolding.
During nervous system development, DR6 plays an essential role in developmental axon pruning, particularly in the corpus callosum and visual system. The receptor mediates axonal degeneration through a pathway that requires the APP cytoplasmic domain and involves local caspase activation. This pruning process is critical for proper neural circuit formation and refinement.
DR6 is expressed on various immune cell populations including T cells, B cells, and macrophages. The receptor modulates immune cell activation, proliferation, and cytokine production. DR6 signaling can both promote and inhibit immune responses depending on the cellular context and available co-receptors.
DR6 has emerged as a significant contributor to Alzheimer's disease pathogenesis through multiple mechanisms. The receptor is highly expressed in brain regions severely affected by AD pathology, including the hippocampus and entorhinal cortex.
Amyloid-beta Induced Apoptosis: DR6 mediates beta-amyloid induced neuronal apoptosis through activation of caspase-6[@nikolaev2009]. The amyloid precursor protein (APP) directly interacts with DR6, and this interaction is enhanced by Aβ oligomers. The activation of DR6 by Aβ leads to downstream caspase activation and eventual neuronal death.
Synaptic Dysfunction: DR6 localizes to synapses where it contributes to Aβ-induced synaptic loss[@cheng2022]. Activation of synaptic DR6 triggers caspase-6 activation at the synapse, leading to proteolytic degradation of synaptic proteins and eventual spine elimination. This mechanism may underlie the early synaptic dysfunction observed in AD.
Microglial Activation: DR6 is expressed on microglia and can be activated by soluble DR6 (sDR6) released from neurons, leading to pro-inflammatory microglial activation[@bjork2020]. sDR6 levels are elevated in AD brain tissue and can trigger NF-κB activation and cytokine production in microglia, contributing to chronic neuroinflammation.
Expression in AD Brain: Studies have demonstrated elevated DR6 expression in the brains of AD patients compared to age-matched controls[@rohn2011]. The upregulation is particularly prominent in regions with high plaque and tangle burden, suggesting that DR6 expression may be induced by AD pathology.
DR6 expression is significantly upregulated in ALS motor neurons and may contribute to selective motor neuron vulnerability. The receptor may interact with TDP-43 proteinopathy, a hallmark of ALS pathology. DR6-mediated apoptosis could contribute to the progressive loss of motor neurons observed in ALS patients.
Emerging evidence suggests DR6 may play a role in Parkinson's disease pathogenesis. DR6 is expressed in dopaminergic neurons of the substantia nigra, and its expression is altered in PD models. The receptor may contribute to dopaminergic neuron death through both apoptotic and neuroinflammatory mechanisms.
DR6 expression is altered in multiple sclerosis lesions and contributes to demyelination and axonal injury. The receptor is expressed on oligodendrocytes and myelin-producing cells, where it may regulate cell survival and myelin maintenance.
DR6 contributes to neuronal injury following ischemic stroke through apoptotic mechanisms. Targeting DR6 has been proposed as a neuroprotective strategy to reduce infarct size and improve functional outcomes[@chang2021].
Aβ Oligomers / Ligand --> DR6 --> FADD --> Caspase-8 --> Caspase-3/6 --> Apoptosis
DR6 activation recruits FADD through homophilic death domain interactions. FADD then recruits and activates caspase-8, which can directly activate executioner caspases (caspase-3, -6, -7) or cleave Bid to tBid, which translocates to mitochondria to initiate the intrinsic apoptotic pathway.
DR6 can activate both classical and alternative NF-κB signaling pathways through recruitment of adaptor proteins including TRAF2 and RIPK1. NF-κB activation can have dual effects—promoting cell survival through expression of anti-apoptotic genes, or inducing pro-inflammatory gene expression in immune cells.
The amyloid precursor protein (APP) interacts directly with DR6 through its cytoplasmic domain. This interaction is enhanced by Aβ oligomers, which may act as DR6 agonists. The APP-DR6 interaction triggers caspase-6 activation and axonal degeneration independent of classical ligand binding.
DR6 represents a promising therapeutic target for neurodegenerative diseases:
Soluble DR6 (sDR6) in cerebrospinal fluid may serve as a biomarker for neuronal injury and disease progression in AD and other neurodegenerative conditions. sDR6 levels correlate with cognitive decline and brain atrophy in AD patients.
Genome-wide association studies (GWAS) have identified TNFRSF21 variants associated with increased risk for late-onset Alzheimer's disease in multiple populations[@xu2024]. The functional significance of these variants is under investigation, with some potentially affecting DR6 expression levels or signaling efficiency.
Key research questions remain regarding DR6 biology:
The following diagram shows the key molecular relationships involving TNFRSF21 Gene discovered through SciDEX knowledge graph analysis: